C
Cheol-Min Park
Researcher at Ulsan National Institute of Science and Technology
Publications - 39
Citations - 4019
Cheol-Min Park is an academic researcher from Ulsan National Institute of Science and Technology. The author has contributed to research in topics: Cycloaddition & Diazo. The author has an hindex of 18, co-authored 39 publications receiving 3490 citations. Previous affiliations of Cheol-Min Park include Nanyang Technological University & AbbVie.
Papers
More filters
Journal ArticleDOI
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers,Joel D. Leverson,Erwin R. Boghaert,Scott L. Ackler,Nathaniel D. Catron,Jun Chen,Brian D. Dayton,Hong Ding,Sari H. Enschede,Wayne J. Fairbrother,David C.S. Huang,David C.S. Huang,Sarah G. Hymowitz,Sha Jin,Seong Lin Khaw,Seong Lin Khaw,Peter Kovar,Lloyd T. Lam,Jackie Lee,Heather Maecker,Kennan C. Marsh,Kylie D. Mason,Kylie D. Mason,Kylie D. Mason,Michael J. Mitten,Paul Nimmer,Anatol Oleksijew,Chang H. Park,Cheol-Min Park,Cheol-Min Park,Darren C. Phillips,Andrew W. Roberts,Andrew W. Roberts,Andrew W. Roberts,Deepak Sampath,John F. Seymour,John F. Seymour,Morey L. Smith,Gerard M. Sullivan,Stephen K. Tahir,Chris Tse,Michael D. Wendt,Yu Xiao,John Xue,Haichao Zhang,Rod A. Humerickhouse,Saul H. Rosenberg,Steven W. Elmore +47 more
TL;DR: The re-engineering of navitoclax is reported to create a highly potent, orally bioavailable and BCL-2–selective inhibitor, ABT-199, which inhibits the growth of BCL–dependent tumors in vivo and spares human platelets, indicating that selective pharmacological inhibition of Bcl-2 shows promise for the treatment of B CL-2-dependent hematological cancers.
Journal ArticleDOI
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
Cheol-Min Park,Milan Bruncko,Jessica Adickes,Joy Bauch,Hong Ding,Kunzer Aaron R,Kennan C. Marsh,Paul Nimmer,Alexander R. Shoemaker,Xiaohong Song,Stephen K. Tahir,Christin Tse,Wang Xilu,Michael D. Wendt,Xiufen Yang,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +18 more
TL;DR: Targeted modifications at three key positions of 1 resulted in a 20-fold improvement in the pharmacokinetic/pharmacodynamic relationship (PK/PD) between oral exposure (AUC) and in vitro efficacy in human tumor cell lines (EC 50).
Journal ArticleDOI
Rhodium(III)‐Catalyzed Intramolecular Annulation through C ? H Activation: Total Synthesis of (±)‐Antofine, (±)‐Septicine, (±)‐Tylophorine, and Rosettacin
Xianxiu Xu,Yu Liu,Cheol-Min Park +2 more
TL;DR: The mild, efficient, and practical intramolecular rhodium-catalyzed C-H/N-H bond functionalization reaction provides isoquinolones with a reverse regioselectivity compared to the reported intermolecular version.
Journal ArticleDOI
Expedient synthesis of highly substituted pyrroles via tandem rearrangement of α-diazo oxime ethers
TL;DR: Novel rearrangements of α-oximino ketenes derived from α-diazo oxime ethers provides 2H-azirines bearing quaternary centers and allows for subsequent rearrangement to highly substituted pyrroles in excellent yields.
Journal ArticleDOI
Synthesis of Pyridines by Carbenoid‐Mediated Ring Opening of 2H‐Azirines
TL;DR: In this article, a novel strategy of activation of 2H-aziridines provides a broad range of highly conjugated poly-arylpyridine systems by formal [3 + 3]-cycloaddition.